{"id":"https://openalex.org/W7213560921","doi":"https://doi.org/10.64898/2026.09.16.26363246","title":"Cost-Effectiveness of Daraxonrasib vs Chemotherapy in Previously Treated Metastatic Pancreatic Adenocarcinoma","display_name":"Cost-Effectiveness of Daraxonrasib vs Chemotherapy in Previously Treated Metastatic Pancreatic Adenocarcinoma","publication_year":2026,"publication_date":"2026-09-17","ids":{"openalex":"https://openalex.org/W7213560921","doi":"https://doi.org/10.64898/2026.09.16.26363246"},"language":"en","primary_location":{"id":"doi:10.64898/2026.09.16.26363246","doi":"https://doi.org/10.64898/2026.09.16.26363246","is_oa":true,"landing_page_url":"https://doi.org/10.64898/2026.09.16.26363246","pdf_url":"https://www.medrxiv.org/content/medrxiv/early/2026/09/17/2026.09.16.26363246.full.pdf","source":{"id":"https://openalex.org/S3005729997","display_name":"medRxiv","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":["https://openalex.org/P4310315909"],"host_organization_lineage_names":["Cold Spring Harbor Laboratory Press"],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"medRxiv","raw_type":"posted-content"},"volume":null,"type":"preprint","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://www.medrxiv.org/content/medrxiv/early/2026/09/17/2026.09.16.26363246.full.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5024332631","display_name":"Sunwoo Han","orcid":"https://orcid.org/0000-0001-6874-2471","observed_orcids":["https://orcid.org/0000-0001-6874-2471"]},"institutions":[{"id":"https://openalex.org/I145608581","display_name":"University of Miami","ror":"https://ror.org/02dgjyy92","country_code":"US","type":"education","lineage":["https://openalex.org/I145608581"]},{"id":"https://openalex.org/I19700959","display_name":"Florida International University","ror":"https://ror.org/02gz6gg07","country_code":"US","type":"education","lineage":["https://openalex.org/I19700959"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sunwoo Han","raw_affiliation_strings":["Department of Biostatistics, Florida International University, Miami, FL","Department of Public Health Sciences, University of Miami, Miami, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biostatistics, Florida International University, Miami, FL","institution_ids":["https://openalex.org/I19700959"]},{"raw_affiliation_string":"Department of Public Health Sciences, University of Miami, Miami, FL","institution_ids":["https://openalex.org/I145608581"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5140983040","display_name":"Natallia Starasvetskaya","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Natallia Starasvetskaya","raw_affiliation_strings":["Coral West Community Hospital, Miami, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Coral West Community Hospital, Miami, FL","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015018124","display_name":"Gretel Terrero","orcid":"https://orcid.org/0000-0003-1510-2555","observed_orcids":["https://orcid.org/0000-0003-1510-2555"]},"institutions":[{"id":"https://openalex.org/I145608581","display_name":"University of Miami","ror":"https://ror.org/02dgjyy92","country_code":"US","type":"education","lineage":["https://openalex.org/I145608581"]},{"id":"https://openalex.org/I4210157065","display_name":"Sylvester Comprehensive Cancer Center","ror":"https://ror.org/0552r4b12","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I145608581","https://openalex.org/I4210101935","https://openalex.org/I4210157065"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gretel Terrero","raw_affiliation_strings":["Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, Miami, FL., 1120 NW 14th St, Suite 650L, Miami, FL 33136., glopes@med.miami.edu"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, Miami, FL., 1120 NW 14th St, Suite 650L, Miami, FL 33136., glopes@med.miami.edu","institution_ids":["https://openalex.org/I145608581","https://openalex.org/I4210157065"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065012486","display_name":"Peter J. Hosein","orcid":"https://orcid.org/0000-0001-8537-6397","observed_orcids":["https://orcid.org/0000-0001-8537-6397"]},"institutions":[{"id":"https://openalex.org/I145608581","display_name":"University of Miami","ror":"https://ror.org/02dgjyy92","country_code":"US","type":"education","lineage":["https://openalex.org/I145608581"]},{"id":"https://openalex.org/I4210157065","display_name":"Sylvester Comprehensive Cancer Center","ror":"https://ror.org/0552r4b12","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I145608581","https://openalex.org/I4210101935","https://openalex.org/I4210157065"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Peter J. Hosein","raw_affiliation_strings":["Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, Miami, FL., 1120 NW 14th St, Suite 650L, Miami, FL 33136., glopes@med.miami.edu"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, Miami, FL., 1120 NW 14th St, Suite 650L, Miami, FL 33136., glopes@med.miami.edu","institution_ids":["https://openalex.org/I145608581","https://openalex.org/I4210157065"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5068401391","display_name":"Gilberto De Lima Lopes Jr.","orcid":"https://orcid.org/0000-0002-1151-9903","observed_orcids":["https://orcid.org/0000-0002-1151-9903"]},"institutions":[{"id":"https://openalex.org/I145608581","display_name":"University of Miami","ror":"https://ror.org/02dgjyy92","country_code":"US","type":"education","lineage":["https://openalex.org/I145608581"]},{"id":"https://openalex.org/I4210157065","display_name":"Sylvester Comprehensive Cancer Center","ror":"https://ror.org/0552r4b12","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I145608581","https://openalex.org/I4210101935","https://openalex.org/I4210157065"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Gilberto de Lima Lopes","raw_affiliation_strings":["Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, Miami, FL., 1120 NW 14th St, Suite 650L, Miami, FL 33136., glopes@med.miami.edu"],"raw_orcid":"https://orcid.org/0000-0002-1151-9903","affiliations":[{"raw_affiliation_string":"Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, Miami, FL., 1120 NW 14th St, Suite 650L, Miami, FL 33136., glopes@med.miami.edu","institution_ids":["https://openalex.org/I145608581","https://openalex.org/I4210157065"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5068401391"],"corresponding_institution_ids":["https://openalex.org/I145608581","https://openalex.org/I4210157065"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.8574000000953674,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.8574000000953674,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10231","display_name":"Pancreatic and Hepatic Oncology Research","score":0.11159999668598175,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12708","display_name":"Economic and Financial Impacts of Cancer","score":0.015699999406933784,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/daraxonrasib","display_name":"daraxonrasib","score":0.8550000190734863},{"id":"https://openalex.org/keywords/metastatic-pancreatic-adenocarcinoma","display_name":"metastatic pancreatic adenocarcinoma","score":0.9409999847412109},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.8610000014305115},{"id":"https://openalex.org/keywords/ras-targeted-therapy","display_name":"RAS-targeted therapy","score":0.8019999861717224},{"id":"https://openalex.org/keywords/chemotherapy","display_name":"chemotherapy","score":0.6549999713897705},{"id":"https://openalex.org/keywords/incremental-cost-effectiveness-ratio","display_name":"incremental cost-effectiveness ratio","score":0.8420000076293945},{"id":"https://openalex.org/keywords/quality-adjusted-life-years","display_name":"quality-adjusted life years","score":0.8930000066757202},{"id":"https://openalex.org/keywords/drug-pricing","display_name":"drug pricing","score":0.6349999904632568},{"id":"https://openalex.org/keywords/previously-treated-patients","display_name":"previously treated patients","score":0.5239999890327454},{"id":"https://openalex.org/keywords/willingness-to-pay-threshold","display_name":"willingness-to-pay threshold","score":0.6800000071525574},{"id":"https://openalex.org/keywords/oncology-drug-costs","display_name":"oncology drug costs","score":0.5210000276565552},{"id":"https://openalex.org/keywords/partitioned-survival-model","display_name":"partitioned survival model","score":0.5690000057220459}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8673999905586243},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.6628000140190125},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6327999830245972},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6090999841690063},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5246999859809875},{"id":"https://openalex.org/C2780258809","wikidata":"https://www.wikidata.org/wiki/Q414143","display_name":"Gemcitabine","level":3,"score":0.47099998593330383},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.45899999141693115},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.4530999958515167},{"id":"https://openalex.org/C2781182431","wikidata":"https://www.wikidata.org/wiki/Q356033","display_name":"Adenocarcinoma","level":3,"score":0.4505000114440918},{"id":"https://openalex.org/C2992026798","wikidata":"https://www.wikidata.org/wiki/Q212961","display_name":"Pancreatic ductal adenocarcinoma","level":4,"score":0.4066999852657318},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.38089999556541443},{"id":"https://openalex.org/C2776291640","wikidata":"https://www.wikidata.org/wiki/Q2912517","display_name":"Value (mathematics)","level":2,"score":0.35109999775886536},{"id":"https://openalex.org/C2910665457","wikidata":"https://www.wikidata.org/wiki/Q356033","display_name":"Metastatic adenocarcinoma","level":4,"score":0.3393999934196472},{"id":"https://openalex.org/C2778336483","wikidata":"https://www.wikidata.org/wiki/Q5090632","display_name":"Chemotherapy regimen","level":3,"score":0.33559998869895935},{"id":"https://openalex.org/C3019080777","wikidata":"https://www.wikidata.org/wiki/Q1754768","display_name":"Cost effectiveness","level":2,"score":0.31839999556541443},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.2824000120162964},{"id":"https://openalex.org/C127454912","wikidata":"https://www.wikidata.org/wiki/Q942582","display_name":"Cost\u2013benefit analysis","level":2,"score":0.28040000796318054},{"id":"https://openalex.org/C515549039","wikidata":"https://www.wikidata.org/wiki/Q1754768","display_name":"Cost-effectiveness analysis","level":3,"score":0.2750000059604645},{"id":"https://openalex.org/C66887028","wikidata":"https://www.wikidata.org/wiki/Q382444","display_name":"Marginal cost","level":2,"score":0.27480000257492065},{"id":"https://openalex.org/C2776125615","wikidata":"https://www.wikidata.org/wiki/Q18391886","display_name":"Economic evaluation","level":2,"score":0.2736000120639801},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.27129998803138733},{"id":"https://openalex.org/C2780283643","wikidata":"https://www.wikidata.org/wiki/Q2110267","display_name":"Primary tumor","level":4,"score":0.26930001378059387},{"id":"https://openalex.org/C2780210213","wikidata":"https://www.wikidata.org/wiki/Q212961","display_name":"Pancreatic cancer","level":3,"score":0.2630999982357025},{"id":"https://openalex.org/C2779013556","wikidata":"https://www.wikidata.org/wiki/Q181876","display_name":"Metastasis","level":3,"score":0.25459998846054077},{"id":"https://openalex.org/C70587473","wikidata":"https://www.wikidata.org/wiki/Q7834111","display_name":"Transformative learning","level":2,"score":0.25110000371932983}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.64898/2026.09.16.26363246","doi":"https://doi.org/10.64898/2026.09.16.26363246","is_oa":true,"landing_page_url":"https://doi.org/10.64898/2026.09.16.26363246","pdf_url":"https://www.medrxiv.org/content/medrxiv/early/2026/09/17/2026.09.16.26363246.full.pdf","source":{"id":"https://openalex.org/S3005729997","display_name":"medRxiv","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":["https://openalex.org/P4310315909"],"host_organization_lineage_names":["Cold Spring Harbor Laboratory Press"],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"medRxiv","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.64898/2026.09.16.26363246","doi":"https://doi.org/10.64898/2026.09.16.26363246","is_oa":true,"landing_page_url":"https://doi.org/10.64898/2026.09.16.26363246","pdf_url":"https://www.medrxiv.org/content/medrxiv/early/2026/09/17/2026.09.16.26363246.full.pdf","source":{"id":"https://openalex.org/S3005729997","display_name":"medRxiv","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":["https://openalex.org/P4310315909"],"host_organization_lineage_names":["Cold Spring Harbor Laboratory Press"],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"medRxiv","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7213560921.pdf","grobid_xml":"https://content.openalex.org/works/W7213560921.grobid-xml"},"referenced_works_count":12,"referenced_works":["https://openalex.org/W1982967337","https://openalex.org/W2058056848","https://openalex.org/W2788249140","https://openalex.org/W3118389339","https://openalex.org/W3196635245","https://openalex.org/W3204826579","https://openalex.org/W4206121490","https://openalex.org/W4283328969","https://openalex.org/W4402593028","https://openalex.org/W4405523408","https://openalex.org/W4408391963","https://openalex.org/W7162952636"],"related_works":["https://openalex.org/W7162952636","https://openalex.org/W7214194264","https://openalex.org/W7168662012","https://openalex.org/W7163317289","https://openalex.org/W7164556996","https://openalex.org/W7167672052","https://openalex.org/W7162683357","https://openalex.org/W7163156740","https://openalex.org/W7154728896","https://openalex.org/W7164538899"],"abstract_inverted_index":{"Abstract":[0],"Introduction":[1],"Daraxonrasib":[2,171,370],"is":[3,35,69],"the":[4,24,74,109,138,146,150,182,206,234,268,288,305,351,359,363,424,431,434],"first":[5],"broad":[6],"RAS-targeted":[7],"medicine":[8],"approved":[9],"for":[10,457],"metastatic":[11,85,379],"pancreatic":[12,86,380],"adenocarcinoma.":[13],"In":[14,233,284],"RASolute":[15,114],"302,":[16],"it":[17],"approximately":[18,354,404],"doubled":[19,372],"median":[20,373,384],"overall":[21,151,374],"survival":[22,105,334,375,385],"in":[23,82,157,162,223,304,376,382],"prespecified":[25],"RAS":[26,132,235,269,306],"G12":[27,133,236,270,307],"population.":[28],"The":[29,58,131,258],"US":[30,166,225,411],"wholesale":[31],"acquisition":[32,416],"cost":[33,250],"(WAC)":[34],"$39,800":[36],"per":[37,311,406,445],"30-day":[38,207],"supply.":[39],"Contemporary":[40],"oncology":[41,64],"launch":[42],"prices":[43,303,417,439],"have":[44,52],"risen":[45],"substantially,":[46],"and":[47,92,97,120,189,205,218,227,243,296,298,316,323,336,368,393,459],"many":[48],"recently":[49],"launched":[50],"drugs":[51],"been":[53],"priced":[54],"above":[55,409],"value-based":[56],"benchmarks.":[57,412],"value":[59],"of":[60,76,214,251,256,290,321,358],"a":[61,102,165,340],"genuinely":[62],"transformative":[63],"therapy":[65],"at":[66,122,229,247,294,300,314,318,433],"this":[67],"price":[68,209],"uncertain.":[70],"Objective":[71],"To":[72],"estimate":[73,352],"cost-effectiveness":[75,198,291],"daraxonrasib":[77,208,238,402],"compared":[78],"with":[79,211,356,386,441],"investigator\u2019s-choice":[80,178],"chemotherapy":[81,388],"previously":[83,377],"treated":[84,378],"adenocarcinoma":[87],"using":[88,101,274,331],"publicly":[89],"available":[90,396],"clinical":[91],"economic":[93,148],"data.":[94,130],"Design,":[95],"Setting,":[96],"Participants":[98],"Economic":[99],"evaluation":[100],"3-state":[103],"partitioned":[104],"model":[106],"informed":[107],"by":[108,278],"international":[110],"randomized":[111,152],"phase":[112],"3":[113],"302":[115],"trial.":[116],"Published":[117],"Kaplan-Meier":[118],"curves":[119,335],"numbers":[121],"risk":[123],"were":[124,160,221,309,443],"used":[125],"to":[126,137,181,272,347,362,397],"reconstruct":[127],"pseudo-individual":[128],"patient":[129],"population":[134,153,308],"(n=459),":[135],"corresponding":[136,259],"trial\u2019s":[139],"dual":[140],"primary":[141,147],"efficacy":[142],"end":[143],"points,":[144],"was":[145,155,262,292,389],"population;":[149],"(n=500)":[154],"analyzed":[156],"parallel.":[158],"Analyses":[159],"conducted":[161],"2026":[163,224],"from":[164,325,451],"health":[167],"sector":[168],"perspective.":[169],"Exposures:":[170],"300":[172],"mg":[173],"orally":[174],"once":[175],"daily":[176],"versus":[177],"chemotherapy,":[179],"weighted":[180],"observed":[183,348],"trial":[184],"regimen":[185],"distribution.":[186],"Main":[187],"Outcomes":[188],"Measures":[190],"Incremental":[191],"life-years,":[192],"quality-adjusted":[193],"life-years":[194,242],"(QALYs),":[195],"costs,":[196],"incremental":[197,201,249],"ratio":[199],"(ICER),":[200],"net":[202,415,435],"monetary":[203],"benefit,":[204],"consistent":[210,440],"willingness-to-pay":[212],"thresholds":[213],"$100,000,":[215],"$150,000,":[216],"$200,000,":[217],"$255,000/QALY.":[219,301],"Costs":[220],"expressed":[222],"dollars":[226],"discounted":[228],"3%":[230],"annually.":[231],"Results":[232],"population,":[237],"generated":[239],"0.652":[240],"additional":[241,245],"0.506":[244],"QALYs":[246],"an":[248,254],"$253,171,":[252],"yielding":[253],"ICER":[255,261,271,425,432],"$500,637/QALY.":[257],"overall-population":[260],"$542,255/QALY.":[263],"A":[264],"10-year":[265],"horizon":[266],"changed":[267],"$497,270/QALY;":[273],"curve-specific":[275],"distributions":[276],"selected":[277],"Akaike":[279],"information":[280],"criterion":[281],"produced":[282,339],"$493,895/QALY.":[283],"5000":[285],"probabilistic":[286],"simulations,":[287],"probability":[289],"0%":[293],"$150,000":[295],"$200,000/QALY":[297],"0.1%":[299],"Threshold":[302,437],"$14,060":[310],"30":[312,446],"days":[313,447],"$150,000/QALY":[315],"$17,730":[317],"$200,000/QALY,":[319],"reductions":[320],"64.7%":[322],"55.5%":[324],"WAC.":[326],"An":[327],"independent":[328],"secondary":[329],"implementation":[330],"separately":[332],"digitized":[333],"piecewise-exponential":[337],"extrapolation":[338],"higher":[341],"ICER;":[342],"after":[343],"calibrating":[344],"drug":[345],"exposure":[346],"treatment":[349],"duration,":[350],"remained":[353],"$676,000/QALY,":[355],"most":[357],"difference":[360],"attributable":[361],"extrapolated":[364],"treatment-exposure":[365],"tail.":[366],"Conclusions":[367],"Relevance":[369],"nearly":[371],"adenocarcinoma,":[381],"which":[383],"standard":[387],"about":[390],"7":[391],"months,":[392],"should":[394],"remain":[395],"eligible":[398],"patients.":[399],"At":[400],"WAC,":[401],"costs":[403],"$500,000":[405],"QALY,":[407],"well":[408],"conventional":[410],"Because":[413],"actual":[414],"may":[418,429],"reflect":[419],"confidential":[420],"discounts":[421],"or":[422],"rebates,":[423],"based":[426],"on":[427],"WAC":[428],"exceed":[430],"price.":[436],"list":[438],"$150,000-$200,000/QALY":[442],"$14,060-$17,730":[444],"(a":[448],"55%-65%":[449],"reduction":[450],"WAC),":[452],"offered":[453],"as":[454],"reference":[455],"points":[456],"pricing":[458],"coverage":[460],"discussions":[461],"rather":[462],"than":[463],"recommended":[464],"prices.":[465]},"counts_by_year":[],"updated_date":"2026-11-09T13:22:03.289127","created_date":"2026-09-18T00:00:00"}